Sign in →

Order Code CEA Carcinoembryonic Antigen (CEA), Serum

Additional Codes

Epic Order ID LAB57

Reporting Name

Carcinoembryonic Ag (CEA), S

Useful For

Monitoring colorectal cancer and selected other cancers such as medullary thyroid carcinoma

 

May be useful in assessing the effectiveness of chemotherapy or radiation treatment

 

This test is not useful for screening the general population for undetected cancers.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions:

1. Serum gel tubes should be centrifuged within 2 hours of collection.

2. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days

Reference Values

Nonsmokers: ≤3.0 ng/mL

Some smokers may have elevated CEA, usually <5.0 ng/mL.

Serum markers are not specific for malignancy, and values may vary by method.

Day(s) Performed

Monday through Friday

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

82378

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CEA Carcinoembryonic Ag (CEA), S 83085-1

 

Result ID Test Result Name Result LOINC Value
CEA Carcinoembryonic Ag (CEA), S 83085-1

Clinical Information

Carcinoembryonic antigen (CEA) is a glycoprotein normally found in embryonic entodermal epithelium.

 

Increased levels may be found in patients with primary colorectal cancer or other malignancies including medullary thyroid carcinoma and breast, gastrointestinal tract, liver, lung, ovarian, pancreatic, and prostatic cancers.

 

Serial monitoring of CEA should begin prior to therapy to verify post therapy decrease in concentration and to establish a baseline for evaluating possible recurrence. Levels generally return to normal within 1 to 4 months after removal of cancerous tissue.

Clinical Reference

1. Sturgeon C: Tumor markers. In: Rifai N, Horvath AR, Wittwer CT, eds: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:436-478

2. Locker, GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327

3. Moertel CG, Fleming TR, Macdonald JS, et al: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943-947

Report Available

1 to 3 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
 

Method Name

Immunoenzymatic Assay

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Secondary ID

8521